利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

57 条记录 (耗时 0.029 秒)

    Genetically modified ecarin and process for producing the same
    4.
    发明申请
    Genetically modified ecarin and process for producing the same 审中-公开
    转基因茄子及其生产方法

    公开(公告)号：US20050164365A1

    公开(公告)日：2005-07-28

    申请号：US10482925

    申请日：2002-07-04

    申请人： Hiroshi Yonemura ,  Takayuki Imamura ,  Hiroshi Nakatake ,  Kenji Soejima ,  Chikateru Nozaki

    发明人： Hiroshi Yonemura ,  Takayuki Imamura ,  Hiroshi Nakatake ,  Kenji Soejima ,  Chikateru Nozaki

    IPC分类号： C12N9/64 ,  C12N15/12 ,  C07H21/04 ,  C12N1/21 ,  C12N5/06 ,  C12N15/74

    CPC分类号： C12N9/6418

    摘要： A recombinant ecarin protein that specifically activates prothrombin, said protein being efficiently prepared by the genetic engineering technique comprising the steps: (1) culturing a transformant microorganism or animal cell transformed with an expression vector in which a gene encoding ecarin is incorporated to the downstream of a promoter so as to produce and accumulate ecarin in culture supernatant or within said transformant and recovering the produced ecarin; and (2) purifying a solution containing the recovered ecarin to obtain purified ecarin. The present invention allows for production of recombinant ecarin on an industrial scale.

    摘要翻译： 一种特异性激活凝血酶原的重组ecarin蛋白，所述蛋白通过遗传工程技术有效地制备，包括以下步骤：（1）培养用表达载体转化的转化体微生物或动物细胞，其中将编码ecarin的基因并入到 促进剂，以在培养上清液或所述转化体内产生和积累ecarin并回收所产生的ecarin; 和（2）纯化含有回收的ecarin的溶液以获得纯化的ecarin。 本发明允许以工业规模生产重组ecarin。

    Hemostatic material
    5.
    发明申请
    Hemostatic material 审中-公开
    止血材料

    公开(公告)号：US20070224251A1

    公开(公告)日：2007-09-27

    申请号：US11385750

    申请日：2006-03-22

    申请人： Masao Tanihara ,  Hisao Kinoshita ,  Takayuki Imamura ,  Chikateru Nozaki

    发明人： Masao Tanihara ,  Hisao Kinoshita ,  Takayuki Imamura ,  Chikateru Nozaki

    IPC分类号： A61K38/48 ,  A61L15/00

    CPC分类号： A61K38/4833 ,  A61L15/225 ,  A61L15/32 ,  A61L24/043 ,  A61L24/10 ,  A61L2400/04

    摘要： The present invention provides a hemostatic material which is excellent in hemostatic property, biodegradability and bioabsorbability, uniformity and stability of the quality, as well as reduces a risk of contamination with a pathogenic organism derived from an animal. The hemostatic material comprises a thrombin and a synthetic polypeptide capable of forming a triple helical structure. The polypeptide may show a peak of the molecular weight in the range from 5×104 to 100×104 in the molecular weight distribution. The polypeptide may contain at least a peptide unit represented by the formula: -Pro-X-Gly- (in the formula, X represents Pro or Hyp). The thrombin may be a recombinant. In the hemostatic material, the proportion of the thrombin may be about 0.1 to 500 units (U) relative to 1 mg of the polypeptide. The hemostatic material may further comprise a binder component having biodegradability and bioabsorbability. The hemostatic material may be formed on a substrate.

    摘要翻译： 本发明提供止血性，生物降解性和生物吸收性，质量的均匀性和稳定性优异的止血材料，并且降低了来自动物的病原体的污染的风险。 止血材料包含能够形成三重螺旋结构的凝血酶和合成多肽。 多肽可以在分子量分布中显示分子量在5×10 4至1​​00×10 4范围内的峰。 多肽可以至少含有由下式表示的肽单元：-Pro-X-Gly-（在该式中，X表示Pro或Hyp）。 凝血酶可以是重组体。 在止血材料中，相对于1mg多肽，凝血酶的比例可以为约0.1至500单位（U）。 止血材料还可以包含具有生物降解性和生物吸收性的粘合剂组分。 止血材料可以形成在基底上。

    Method for using inactivated Japanese encephalitis virus particles as adjuvant
    6.
    发明授权
    Method for using inactivated Japanese encephalitis virus particles as adjuvant 有权
    使用灭活的日本脑炎病毒颗粒作为佐剂的方法

    公开(公告)号：US09114098B2

    公开(公告)日：2015-08-25

    申请号：US12996236

    申请日：2009-05-27

    申请人： Makoto Moriyama ,  Kazuyoshi Kaminaka ,  Junichi Matsuda ,  Chikateru Nozaki

    发明人： Makoto Moriyama ,  Kazuyoshi Kaminaka ,  Junichi Matsuda ,  Chikateru Nozaki

    IPC分类号： C07K14/18 ,  A61K39/00

    CPC分类号： A61K39/00 ,  A61K2039/5252 ,  A61K2039/55588 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/464 ,  Y02A50/466 ,  Y02A50/472 ,  Y02A50/484

    摘要： A method for using inactivated Japanese encephalitis virus particles as an adjuvant of a vaccine is provided. A method for using inactivated Japanese encephalitis virus (JEV) particles as an adjuvant of various vaccines or a mixed vaccine, said JEV particles being obtained by inoculating JEV Beijing-1 strain to Vero cells, culturing said JEV-infected cells to give cultured cells or culture supernatant, purifying JEV particles from said cultured cells or culture supernatant and inactivating said JEV particles with formalin, a method for preparing a (mixed) vaccine which comprises a step of letting inactivated Japanese encephalitis virus be contained, and a mixed vaccine prepared by said method.

    摘要翻译： 提供了使用灭活的日本脑炎病毒颗粒作为疫苗佐剂的方法。 使用灭活的日本脑炎病毒（JEV）颗粒作为各种疫苗或混合疫苗的佐剂的方法，所述JEV颗粒通过将JEV Beijing-1菌株接种到Vero细胞获得，培养所述JEV感染的细胞以产生培养的细胞或 培养上清液，从所述培养细胞或培养上清液中纯化JEV颗粒，并用福尔马林灭活所述JEV颗粒，制备包含使灭活的日本脑炎病毒的步骤的（混合）疫苗的方法，以及由所述 方法。

    Method for enhancing immune response with peptide
    7.
    发明授权
    Method for enhancing immune response with peptide 有权
    用肽增强免疫应答的方法

    公开(公告)号：US08106015B2

    公开(公告)日：2012-01-31

    申请号：US12596741

    申请日：2008-04-18

    申请人： Junichi Matsuda ,  Kazuyoshi Kaminaka ,  Chikateru Nozaki

    发明人： Junichi Matsuda ,  Kazuyoshi Kaminaka ,  Chikateru Nozaki

    IPC分类号： A61K38/17 ,  A61K39/00 ,  A61P25/00 ,  A61P37/04 ,  C07K14/435

    CPC分类号： A61K39/0007 ,  A61K31/711 ,  C07K14/4711

    摘要： An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid β peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid β peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine.

    摘要翻译： 本发明的目的是提供一种用于增强免疫应答的安全有效的方法和用于预防或治疗阿尔茨海默氏病的药物，其包括淀粉样蛋白 诱导增强的免疫应答的肽。 淀粉样蛋白 肽或其部分，其中加入或插入半胱氨酸，以及使用肽增强免疫应答的方法或使用肽与佐剂一起增强免疫应答的方法。 一种用于预防或治疗阿尔茨海默病的药物，其包含淀粉样蛋白 肽或其部分诱导增强的免疫应答。 可能具有相同作用的DNA疫苗，其包含编码淀粉样蛋白的基因; 肽或其部分，其通过加入或插入半胱氨酸诱导增强的免疫应答。

    PROPHYLACTIC OR THERAPEUTIC AGENT FOR CORNEAL/CONJUNCTIVAL DISEASE
    8.
    发明申请
    PROPHYLACTIC OR THERAPEUTIC AGENT FOR CORNEAL/CONJUNCTIVAL DISEASE 审中-公开
    预防或治疗神经系统疾病

    公开(公告)号：US20100113338A1

    公开(公告)日：2010-05-06

    申请号：US11993580

    申请日：2006-06-21

    申请人： Masanao Watanabe ,  Kazuo Tsubota ,  Masaki Hirashima ,  Chikateru Nozaki

    发明人： Masanao Watanabe ,  Kazuo Tsubota ,  Masaki Hirashima ,  Chikateru Nozaki

    IPC分类号： A61K38/16 ,  C07K14/00 ,  A61P27/02

    CPC分类号： A61K38/1761 ,  A61K9/0048

    摘要： Disclosed is a novel composition for the treatment of a corneal/conjunctival disease. A prophylactic or therapeutic agent for a corneal/conjunctival disease comprising selenoprotein P as an active ingredient, more specifically a prophylactic or therapeutic agent for a corneal/conjunctival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer comprising selenoprotein P as an active ingredient, particularly a prophylactic or therapeutic agent for a corneal/conjuncrtival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer accompanied by a corneal/conjunctival epithelial discorder.

    摘要翻译： 公开了用于治疗角膜/结膜疾病的新型组合物。 一种用于角膜/结膜疾病的预防或治疗剂，其包含硒蛋白P作为活性成分，更具体地，涉及用于角膜/结膜疾病如干眼症，圆锥形结膜炎丝氨酸，浅表性点状角膜病，角膜侵蚀或角膜溃疡的预防或治疗剂，其包括 硒蛋白P作为活性成分，特别是用于角膜/结膜性疾病例如干眼症，透角圆锥形结膜炎，浅表性点状角膜病变，伴随角膜/结膜上皮发生器的角膜侵蚀或角膜溃疡的预防或治疗剂。

    Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same
    9.
    发明申请
    Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same 有权
    针对酶的抗体特异性切割von villebrand因子和使用其的测定系统

    公开(公告)号：US20060251655A1

    公开(公告)日：2006-11-09

    申请号：US10529009

    申请日：2003-09-25

    申请人： Kenji Soejima ,  Noriko Mimura ,  Hiroaki Maeda ,  Chikateru Nozaki ,  Takayoshi Hamamoto ,  Tomohiro Nakagaki

    发明人： Kenji Soejima ,  Noriko Mimura ,  Hiroaki Maeda ,  Chikateru Nozaki ,  Takayoshi Hamamoto ,  Tomohiro Nakagaki

    IPC分类号： A61K39/395 ,  G01N33/53 ,  C07H21/04 ,  C07K16/40 ,  C12P21/06 ,  C12N5/06

    CPC分类号： C12N9/6489 ,  C07K16/40

    摘要： It is intended to provide an antibody showing immunoreactivity selectively to ADAMTS-13 and applications of this antibody in epitope analysis or diagnosis of an ADAMTS-13 autoantibody-positive patient. Alternatively, it is intended to provide a process for producing and use of a modified ADAMTS-13 molecule partially deleted aiming at the application in pharmaceutical products. An antibody specific for ADAMTS-13 which can be obtained from a warm-blooded animal immunized and sensitized with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; a process for producing an antibody comprising a step of immunizing and sensitizing a warm-blooded animal with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; use of the above-described antibody including a method of detecting and purifying ADAMTS-13; and a modified ADAMTS-13 molecule partially deleted are provided.

    摘要翻译： 旨在提供一种抗体，显示ADAMTS-13的免疫反应性和该抗体在ADAMTS-13自身抗体阳性患者的表位分析或诊断中的应用。 或者，旨在提供一种制备和使用针对在药物产品中应用的部分缺失的修饰的ADAMTS-13分子的方法。 对于ADAMTS-13特异的抗体，其可从用含有部分或全部ADAMTS-13氨基酸序列的多肽免疫并致敏的温血动物获得; 一种制备抗体的方法，其包括用含有部分或全部ADAMTS-13氨基酸序列的多肽对温血动物进行免疫和致敏的步骤; 使用上述抗体，包括检测和纯化ADAMTS-13的方法; 并提供部分缺失的修饰的ADAMTS-13分子。